Posters

    Identifying neuroinflammation in omics datasets with a computational biological network model of reactive astrogliosis

    Barkhuizen, M.; Mathis, C.; Peitsch, M. C.; Talikka, M.

    Conference date
    Jul 26, 2021
    Conference name

    Alzheimer's Association International Conference (AAIC) 2021
    Link to more information
    Topic
    Summary

    Introduction • Reactive astrogliosis is a change in the molecular phenotype of astrocytes in CNS injuries and diseases, including neurodegenerative diseases such as Alzheimer’s disease . • Signaling changes in reactive astrogliosis are heterogeneous and correspond to specific injuries. • Neuroinflammation (and neurodegenerative diseases) induces a neurotoxic "A1" phenotype, and ischemic stroke induces a protective "A2" phenotype. • There is a core set of pan-reactive genes that are regulated by both inflammation and ischemia. • Transcriptomics allows us to capture large-scale changes in gene expression in different disease states; but gaining mechanistic understanding is challenging. • Here, we present a new tool for interpreting transcriptomic data within the context of reactive astrogliosis. Objectives To construct causal biological network (CBN) models for interpreting astrogliosis transcriptomic data, which can: • Facilitate comparison of the extent of reactive astrogliosis between different conditions in a dataset . • Identify key molecular drivers of reactive astrogliosis in the dataset to aid mechanistic interpretation and help identify disease-specific reactive astrogliosis states.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.